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Abstract: 
Background: Personal Activity Intelligence (PAI) is a novel activity metric that translates 
heart rate variations during exercise into a weekly score. Weekly PAI scores assessed at a 
single point in time were found to associate with lower risk of premature cardiovascular 
disease (CVD) mortality in the general healthy population.  However, to date, the associations 
between long-term longitudinal changes in weekly PAI scores and mortality have not been 
explored.  
Purpose: The aim of the present study was to prospectively examine the association between 
change in weekly PAI scores estimated 10 years apart, and risk of mortality from CVD and 
all-causes. 
Methods: We performed a prospective cohort study of 11,870 men and 13,010 women 
without known CVD in Norway. By using data from the Nord-Trøndelag Health Study 
(HUNT) PAI was estimated twice, ten years apart (HUNT1 1984-86 and HUNT2 1995-97). 
Mortality was followed-up until December 31, 2015. Adjusted hazard ratios (AHR) and 95% 
confidence intervals (CI) for death from CVD and all-causes related to temporal changes in 
PAI were estimated using Cox regression analyses.  
Results: During a mean (SD) of 18 (4) years of follow-up, there were 4782 deaths, including 
1560 deaths caused by CVD. Multi-adjusted analyses demonstrated that participants 
achieving a score of ≥100 PAI at both time points had 32% lower risk of CVD mortality 
(AHR 0.68; CI: 0.54-0.86) for CVD mortality and 20% lower risk of all-cause mortality 
(AHR 0.80; CI: 71-0.91) compared with participants obtaining <100 weekly PAI at both 
measurements. For participants having <100 PAI in HUNT1 but ≥100 PAI in HUNT2, the 
AHRs were 0.87 (CI: 0.74-1.03) for CVD mortality, and 0.86 (CI: 0.79-0.95) for all-cause 
mortality. We also found an inverse linear relationship between change in PAI and risk of 
CVD mortality among participants with 0 PAI (P<0.01), and ≤50 PAI (P=0.04) in HUNT1, 
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indicating that an increase in PAI over time is associated with lower risk of mortality. 
Excluding the first three years of follow-up did not substantially alter the findings. Increasing 
PAI score from <100 PAI in HUNT1 to ≥100 PAI in HUNT2 was associated with 6.6 years 
gained lifespan. 
Conclusion: Among men and women without known CVD, an increase in PAI score and 
sustained high PAI score over a 10-year period was associated with lower risk of mortality. 
 
Abbreviations: 
BMI Body Mass Index 
BP Blood pressure 
CRF Cardiorespiratory fitness 
CVD Cardiovascular disease 
DM Diabetes Mellitus 
HDL High Density Lipoprotein 
HTN Hypertension 
HUNT The Nord-Trøndelag health study 
NCD Non-communicable disease 
PA Physical activity 
PAI Personal Activity Intelligence 
TG Triglyceride 
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Introduction 
Non-communicable diseases (NCDs) are the leading cause of mortality worldwide and 
account for 70% of all deaths every year (1, 2). Cardiovascular disease (CVD) is the most 
common type of NCD, and is estimated to be responsible for approximately 17.5 million 
deaths globally (3, 4). There is strong epidemiological evidence demonstrating an inverse 
relationship between physical activity (PA) levels and risk of mortality for CVD and all-
causes (5-8). Prospective studies have shown that increasing PA levels over time reduces the 
risk of CVD and all-cause mortality (6). There is evidence showing that for the same amount 
of PA volume, high intensity PA is associated with greater mortality risk reductions compared 
to moderate or low intensity PA (7, 8). This may be because high intensity PA is superior to 
improve cardiorespiratory fitness (CRF) (9-12), which is inversely associated with CVD risk 
profile and mortality risk in the general population (13-16). Despite this, most of the PA goals 
used in health promotion (10,000 steps per day, 30 minutes of PA per day) do not take 
exercise intensity into consideration. Further, only approximately 30% of the Norwegian 
population and 5% of the American population meet the current PA recommendations (5, 17, 
18). Hence, innovative approaches to promote individual participation in PA are needed (19).  
A major challenge in PA promotion is to provide different options, and individual 
feedback tailored to personal needs and preferences (20). Most available PA metrics in the 
literature fail to translate physiological measures into meaningful, personal and scientifically 
proven information for the mainstream user (21). Recently, we developed a personalized 
activity metric, named Personal Activity Intelligence (PAI) (22). PAI considers the 
individual’s sex, age, resting and maximal heart rates, and reflects individuals’ response to PA 
(22). The metric translates heart rate variations over the course of a week, into a simple and 
easily understandable score (0=inactive, and 100=active enough) (22). For instance, a score of 
100 PAI can be obtained by performing various PA volumes and intensities, as long as the 
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heart rate is elevated above a certain threshold (22). As the PAI metric favors high intensity 
PA, a score of 100 PAI approximates 40 weekly minutes of high intensity PA (≈85% of heart 
rate reserve), or 60 weekly minutes of PA at an intensity of ≈75% of heart rate reserve (22).  
Achieving a score of ≥100 PAI weekly was found to attenuate the association between 
sedentary behavior and CVD risk factor clustering (23). Further, achieving 100 PAI was 
associated with lower risk of mortality from CVD and all-causes in the general healthy 
population, as well as in patients with CVD, independent of meeting PA guidelines (22, 24). 
This suggests that PAI may be a useful tool when quantifying the PA needed to produce 
substantial health benefit in individuals from the general population (22). However, previous 
studies on PAI rely on a single baseline assessment. Potential confounders may bias studies 
addressing single exposure assessment, and PA levels reported at baseline may change during 
follow-up, affecting the risk estimates. Temporal changes in PAI scores and risk of CVD and 
all-cause mortality have not been previously considered. Therefore, the association between 
sustaining a low/adequate PAI score, or increasing/decreasing PAI score over time, and 
mortality is unknown. The aim of this study was to prospectively examine the association 
between changes in weekly PAI scores estimated 10 years apart, and risk of mortality from 
CVD and all-causes.  
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Methods 
Study population 
We included participants aged 20 years and older from the Nord-Trøndelag County who 
participated both in the first (HUNT1, January 1984 to February 1986) and the second 
(HUNT2, August 1995 to June 1997) survey of the Nord-Trøndelag health study. All 
participants provided informed consents, filled out detailed questionnaires about health and 
life style, and attended clinical examinations at both HUNT surveys. Detailed accounts of the 
first and second HUNT surveys have been previously described (25). Of the 77 212 subjects 
who participated in HUNT1, 47 313 (61%) also participated in HUNT2 (25). We excluded 
5006 subjects with self-reported CVD, 3 537 subjects with somatic disease (moderate or 
high), 1 677 subjects with motion impairment (moderate or high) and 12 213 subjects with 
missing values on covariates (Figure 1) (22). The remaining 24 880 participants were 
included in the study. The Regional Ethical Committee for Health research approved the 
study protocol (2017/318/REKmidt). 
 
Clinical Measurements and Questionnaire Based Information 
Trained nurses performed clinical measurements such as height, weight, blood pressure (BP), 
and laboratory measurements, such as non-fasting serum concentrations of glucose, 
triglycerides (TGs), total cholesterol and high-density lipoprotein (HDL) cholesterol. 
Measurement methods are described elsewhere (26). Body mass index (BMI) was categorized 
into four groups according to the World Health Organization’s BMI classification (27). 
Hypertension (HTN) was defined as measured systolic BP ≥140 mmHg or diastolic BP≥90 
mmHg or self-reported use of anti-HTN drugs. Diabetes mellitus (DM) status was determined 
based on self-reported diagnosis or non-fasting glucose levels >11.1 mmol/l (28). High total 
cholesterol was defined as >6.9 mmol/l for participants under 50 years and >7.8 mmol/l for 
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participants above 50 years (29). Low levels of HDL-cholesterol were defined as <1.2 mmol/l 
for women and <1.0 mmol/l for men whereas high levels of TGs were defined as >1.7 mmol/l 
(30). 
Participants with self-reported CVD (myocardial infarction or angina pectoris or stroke/brain 
hemorrhage) were identified using the first HUNT1 and HUNT2 questionnaire (31, 32). 
Information about DM, use of anti-HTN drugs, somatic disease, motion impairment, smoking 
status, alcohol consumption, educational level, and age was also obtained from the first 
HUNT2 questionnaire (32).  
 
Personal Activity Intelligence (PAI) 
Information on leisure time PA was obtained from a self-administered questionnaire. PAI 
scores for each participant, were calculated using the responses to PA questions about 
duration, frequency and intensity in both HUNT1 and HUNT2 (32, 33). The reported intensity 
of PA was translated to relative intensity where low, moderate or vigorous intensity 
corresponded to 44%, 73% and 83% of heart rate reserve, respectively. According to the PAI 
algorithm described elsewhere (22, 23), the weekly minutes spent performing PA were 
obtained by multiplying the average frequency of PA with the average duration of PA. We 
then combined the exercise volumes with the reported exercise intensities by the use of heart 
rate reserves to estimate a weekly PAI score.  
 
Outcomes 
The primary outcome was mortality caused by CVD (International Classification of Diseases, 
ninth revision: 390-459 or International Classification of Diseases, tenth revision: I00-I99), 
and the secondary outcome was mortality from all causes. Data on cause and date of death 
was obtained from the Norwegian cause of death registry, and accurately matched to each 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
participant through their 11-digit personal identification number. Our study had a virtually 
complete follow-up of participants, as registration in the population registers is mandatory in 
Norway. Only participants who emigrated from the country are missing in the analyses 
(≤1%). The participants were followed from their participation date in HUNT2 until their date 
of death or end of follow-up on 31
st
 December 2015.  
 
Statistical analyses 
To compare baseline characteristics, categorical data was assessed using Chi-square test or 
Fisher’s exact test according to the estimated expected values. Continuous data was compared 
using one-way ANOVA with equal or unequal variances. 
To assess the association between change in the weekly PAI score and the risk of 
mortality from CVD and all-causes, the participants’ PAI score achieved in both HUNT1 and 
HUNT2 (collected ten years apart) were divided into two groups: ≥100 PAI and <100 PAI. 
This, resulted in four different categories of change in PAI: <100 PAI at both HUNT1 and 
HUNT2, ≥ 100PAI at HUNT1 and < 100PAI at HUNT2; <100 PAI at HUNT1 and ≥100 PAI 
at HUNT2; ≥100 PAI at both HUNT1 and HUNT2. This cut-off point was chosen a priori 
based on results from previous studies (22, 23). The rate of death per 1 000 person-years was 
estimated in each PAI change group. The four PAI change groups were then compared using 
a Cox regression analysis separately for CVD mortality and all-cause mortality. The first 
model was adjusted for age and sex. The second model was further adjusted for education 
(<10 years; 10-12 years; >12 years), alcohol consumption over two weeks (abstainer; <8 
drinks; 8-14 drinks; >14 drinks), smoking status (yes or no), DM status (yes or no), 
hypertension status (yes or no), BMI (<18.5; 18.5-24.9; 25-29.9; ≥30 kg/m2), total cholesterol 
(normal or high), HDL-cholesterol (low or normal), and TGs (normal or high). In both 
models, attained age was included as the time scale. To test the proportional hazards 
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assumption, Schoenfeld residuals were used and time interactions were added to the variables. 
When the assumption was not met, stratified results are reported. Further, we estimated years 
of life gained as the difference in 10
th
 percentile survival years associated with the four 
different change groups using Laplace regression (34, 35). The analysis was sex adjusted. 
Sub-groups analyses were performed for participants 65 years or older. 
To assess the association between continuous change in PAI and risk of mortality 
from CVD and all-causes, we estimated the difference between obtained PAI in HUNT1 and 
HUNT2, and categorized the differences into groups of 30 PAI to allow for the assessment of 
the trend. As previous physical fitness has been associated with risk of mortality (36), we 
assessed linear trends in different sub-groups of obtained PAI in HUNT1 (0 PAI; 1-50 PAI; 
51-99 PAI; ≥100 PAI), using the multi-adjusted model previously described. Sensitivity 
analyses were performed by excluding the first three years of follow-up.  
Descriptive data are presented as means (standard deviations) and frequencies 
(percentages). Survival data are reported as hazard ratios with 95% confidence intervals. All 
the analyses were performed using Stata version 14.2. All statistical tests were two-sided and 
considered significant at P-value lower than 0.05.  
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RESULTS 
Baseline characteristics of participants are presented in Table 1 and Table 2. At both time 
points (HUNT 1 and/or HUNT 2), participants with a PAI score ≥100 were younger, more 
educated and appeared to be healthier (lower BMI, lower percentage of HTN and DM, and 
more favorable blood biochemistry profiles) compared to participants with a PAI score <100 
(Table 1). Similar results are observed when comparing participants according to their 
temporal change in PAI levels (Table 2).  
During the median follow-up of 19.3 years (interquartile range 18.8-19.9; 447 405 
person-years), there were 4 782 deaths, including 1 560 deaths caused by CVD. Compared to 
participants who sustained low PAI scores (<100 PAI at both HUNT1 and HUNT2), multi-
adjusted analyses demonstrated that participants who sustained high PAI scores (≥100 PAI at 
both HUNT1 and HUNT2) had 32% lower risk of CVD mortality (95% CI: 14% to 46%), and 
20% lower risk of all-cause mortality (95% CI: 9% to 29%) (Table 3). For participants who 
increased their PAI scores over time (PAI score of <100 at HUNT1 and ≥100 at HUNT2), the 
adjusted hazard ratio was 0.87 (95% CI: 0.74 to 1.03) for CVD mortality, and 0.86 (95% CI: 
0.79 to 0.95) for all-cause mortality.  
In the analyses using PAI as continuous variable, we found an inverse linear 
relationship between change in PAI and risk of mortality among participants with PAI score 
of 0 (P=0.003 for all-cause mortality, and P=0.006 for CVD mortality), and PAI score of ≤50 
(P<0.001 for all-cause mortality, and P=0.04 for CVD mortality) at HUNT1, indicating that 
an increase in PAI over time is associated with decreased risk of mortality (Table 4). Among 
participants with >50 PAI at HUNT1, we found no evidence of trend associated with change 
in PAI and risk of mortality. Sensitivity analyses demonstrated that results were not 
substantially altered by excluding the first three years of follow-up (supplementary material 
Table 1 and Table 2).   
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We observed that, adjusted for sex, participants with ≥100 PAI at both HUNT1 and 
HUNT2 had 8.2 (95% CI: 7.4 to 9.0) years of life gained compared to those with <100 PAI at 
both assessments (Figure 2). For those who increased their PAI score over time (<100 PAI at 
HUNT1, ≥100 PAI at HUNT2), the corresponding years gained were 6.6 (95% CI: 5.7 to 7.4), 
whereas participants who were active in HUNT1 (≥100 PAI) but decreased their score had 2.9 
(95% CI: 2.05 to 3.8) years of life gained. For participants who were 65 years or older at 
HUNT2, ≥100 PAI at both assessments was associated with 3.4 (95% CI: 2.3 to 4.5) years of 
life gained, compared to <100 PAI at both HUNT1 and HUNT2 (data not shown).  
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DISCUSSION 
In this prospective study of apparently healthy men and women, we found that an increase in 
PAI over a 10-year period was associated with lower risk of mortality, and that participants 
with a weekly PAI score of ≥100 at both time points had the lowest risk of CVD and all-cause 
mortality.  
PAI levels estimated in HUNT1 were previously found to associate with lower risk of 
mortality among individuals from the general population as well as in patients with CVD (22, 
24), and healthy men and women obtaining ≥100 PAI had respectively 23% and 17% lower 
risk of CVD mortality, and 13% and 17% lower risk of all-cause mortality (22). In this current 
study, we found that obtaining ≥100 PAI at two different points in time is associated with 
32% lower risk of CVD mortality and 20% lower risk of all-cause mortality. Noteworthy, the 
previous study assessing PAI and risk of mortality was only supported by a single PAI 
calculation. However, levels of PA may change over time resulting in a misclassification of 
PA levels. This may bias the results and underestimate the estimated risk reductions (37). In 
this current study, temporal changes in PAI were accounted for, and we found larger risk 
reductions in regard to CVD and all-cause mortality compared to results using a single PAI 
calculation. Therefore, our findings strengthen the knowledge about PAI and health outcomes 
by showing that 100 PAI is strongly related to health and longevity. This may further 
encourage development of PAI and promote adherence to PA using a contemporary and 
innovative approach.  
When studying continuous changes of physical activity, we found a relationship 
between increasing PAI levels over time and risk of mortality from CVD and all-causes, only 
among individuals obtaining ≤50 weekly PAI at HUNT1. PAI takes into account both 
intensity and time spent performing PA, and the PAI score is proportional to intensity of PA: 
when performing PA of the same duration, high intensity earns a higher PAI score compared 
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to moderate or low intensity (22). Therefore, PAI is founded on mechanistic interactions 
between PA and CRF. Interestingly, high levels of CRF in the past, despite low current CRF 
level, has been associated with lower risk of mortality (36). This may explain our current 
findings of association between PAI and risk of mortality only among individuals obtaining 
≤50 PAI at the first measurement. In practical terms, this suggests that encouraging 
individuals to improve their PAI score is most essential among inactive individuals obtaining 
≤50 PAI at first assessment. 
The main strength of the current study was that it was the first study to assess a novel 
metric of PA tracking (PAI) at two different points in time (10 years apart), enabling study of 
behavioral changes in PA in an innovative way. Further, the study has a relatively large 
sample size, a long-term and virtually complete follow up, and a comprehensive source of 
information on possible confounding factors. The study also has some limitations. Data used 
to exclude participants and to estimate PAI was self-reported and therefore prone to 
information bias, however the questionnaires adopted to collect PA data have shown 
acceptable reliability and validity (38, 39). Despite the large number of study participants, the 
number of events in certain sub-groups was low (e.g. only one event among the subgroup of 
individuals obtaining 51-99 PAI in HUNT1 who increased their PAI score by 15 to 45 PAI at 
HUNT2 (Table 4)) which affects the precision of the corresponding effect estimates. 
Therefore, one should be careful in drawing firm conclusions related to these subgroups. 
Moreover, participants included in the current study and in previous studies assessing PAI 
were predominantly Caucasians (22), therefore research on the risk of mortality associated 
with PAI in different races and ethnicities is warranted. Finally, even though participants at 
risk were excluded from the study and results were adjusted for possible known confounders, 
unknown underlying factors may still confound our estimates.  
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The PAI algorithm has recently been integrated into a wearable device and a 
downloadable application (compatible with most Bluetooth enabled heart rate monitors). The 
application analyzes heart rate variations continuously over the course of a week to calculate 
an individual score, providing instant user feedback on the amount of PAIs earned. Physicians 
are able to follow their patients’ PAI score over time as PAI score may be shared between 
patients and physicians. Our findings may therefore encourage physicians to recommend their 
patients to reach 100 PAI and increase their PAI score over time. This may further translate 
into improved health benefits in the general inactive population.  
 
Conclusion: In this prospective study of apparently healthy men and women, an increase in 
PAI and sustained high PAI score of ≥100 PAI obtained ten years apart was associated with 
lower risk of mortality from CVD and all-causes.  
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Figure legends 
Figure 1. Flow of participants 
CVD, cardiovascular disease; HUNT, Helseundersøkelse i Nord-Trøndelag (Nord-Trøndelag 
Health Study); HDL: High density lipoprotein 
Figure 2. Survival curves by PAI score, adjusted for sex 
PAI, Personal Activity Intelligence; H, Helseundersøkelse i Nord-Trøndelag (Nord-Trøndelag 
Health Study) 
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Table 1 Baseline characteristics of study participants by PAI score in HUNT-1 and HUNT-2 
(n=24 880) 
  PAI score in HUNT 1     PAI score in HUNT 2    
 
<100 
 
≥100 
 
P-value <100 
 
≥100 
 
P-value 
  (n=19 386) (n=5 494)   (n=17 643) (n=7 237)   
Age, years, mean (SD) 52.7 (12.8) 50.1 (11.7) <0.001 53.4 (13.0) 48.9  (11.0) <0.001 
BMI, kg/m
2
, mean (SD) 
          
      ≤ 18.5 92 (0.5) 14 (0.3) 
 
82 (0.5) 24 (0.3) 
 
     18.6 - 24.9 7 351 (37.9) 2 294 (41.8) <0.001 6 409 (36.3) 3 236 (44.7) <0.001 
      25.0-29.9 8 760 (45.2) 2 519 (45.9) 
 
8 069 (45.7) 3 210 (44.4) 
 
      ≥ 30.0 3 183 (16.4) 667 (12.1) 
 
3 083 (17.5) 767 (10.6) 
 
Hypertension status, N (%)
1
 
         
      Yes 9 063 (46.8) 2 304 (41.9) <0.001 8 611 (48.8) 2 756 (38.1) <0.001 
      No 10 323 (53.3) 3 190 (58.1) 
 
9 032 (51.2) 4 481 (61.9) 
 
Smoking, N (%) 
          
      Yes 5 747 (29.7) 1 092 (19.9) <0.001 5 192 (29.4) 1 647 (22.8) <0.001 
       No 13 639 (70.4) 4 402 (80.1) 
 
12 451 (70.6) 5 590 (77.2) 
 
Alcohol consumption, N (%)
2
 
         
      Abstainer 2 438 (12.6) 390  (7.1) 
 
2 273 (12.9) 555 (7.7) 
 
      0 - 7 glasses 14 719 (75.9) 4 183 (76.1) <0.001 13 360 (75.7) 5 542 (76.6) <0.001 
      8 - 14 glasses 1 804 (9.3) 741 (13.5) 
 
1 643 (9.3) 902 (12.5) 
 
      >14 glasses 425 (2.2) 180 (3.3) 
 
367 (2.1) 238 (3.3) 
 
Education, N (%) 
          
      < 10 y 7 937 (40.9) 1 436 (26.1) 
 
7 538 (42.7) 1 835 (25.4) 
 
      10-12 y 8 185 (42.2) 2 461 (44.8) <0.001 7 288 (41.3) 3 358 (46.4) <0.001 
      > 12 y 3 264 (16.8) 1 597 (29.1) 
 
2 817 (16.0) 2 044 (28.2) 
 
Diabetes, N (%) 
          
      Yes 512 (2.6) 90 (1.6) <0.001 478 (2.7) 124 (1.7) <0.001 
      No 18 874 (97.4) 5 404 (98.4) 
 
17 165 (97.3) 7 113 (98.3) 
 
Total cholesterol, N (%) 
          
      Normal 17 144 (88.4) 4 965 (90.4) <0.001 15 524 (88.0) 6 585 (91.0) 
 
      High 2 242 (11.6) 529 (9.6) 
 
2 119 (12.0) 652 (9.0) 
 
HDL cholesterol, N (%) 
          
      Low 5 335 (27.5) 1 215 (22.1) <0.001 4 974 (28.2) 1 576 (21.8) <0.001 
      Normal 14 051 (72.5) 4 279 (77.9) 
 
12 669 (71.8) 5 661 (78.2) 
 
Triglycerides, N (%) 
          
      Normal 11 534 (59.5) 3 520 (64.1) <0.001 10 198 (57.8) 4 856 (67.1) <0.001 
      High 7 852 (40.5) 1 974 (35.9) 
 
7 445 (42.2) 2 381 (32.9) 
 
Physical activity, N (%) 
          
    Light intensity 
          
            None 1 489 (8.0) 149 (3.2) 
 
1 571 (9.0) 67 (1.2) 
 
            <1 hour 3 688 (19.9) 517 (11.1) <0.001 3 976 (22.8) 229 (4.0) <0.001 
            1-2 hours 7 419 (40.0) 1 799 (38.6) 
 
7 567 (43.4) 1 651 (28.8) 
 
            ≥3 hours 5 933 (32.0) 2 197 (47.1) 
 
4 335 (24.8) 3 795 (66.1) 
 
      Vigorous intensity 
          
            None 6 574 (45.6) 853 (18.5) 
 
7 427 (63.0) - 
  
            <1 hour 4 134 (28.7) 1 089 (23.6) <0.001 4 365 (37.0) 858 (11.9) <0.001 
            1-2 hours 2 665 (18.5) 1 604 (34.7) 
 
- 
 
4 269 (59.0) 
 
            ≥3 hours 1 033 (7.2) 1 077 (23.3)   -   2 110 (29.2)   
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Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in square meters), 
HDL, High Density Lipoprotein. 
1Defined as measured systolic blood pressure ≥ 140, diastolic blood pressure ≥ 90 or self-reported use of 
antihypertensive drugs.  
2
Based on consumption the last 14 days.  
 
 
 
 
Table 2 Characteristics of study participants according to temporal change in PAI score from 
HUNT1to HUNT2 
    HUNT-2 <100   HUNT-2 ≥100     
  
HUNT-1 
<100 
HUNT-1 
≥100 
HUNT-1 
<100 
HUNT-1 
≥100 
P-value 
    (n=15 008) (n=2 635) (n=4 378) (n=2 859)   
Age, years, mean 
(SD) 
53.8 (13.0) 51.3 (12.5) 48.9  (11.2) 49.0 (10.8) <0.001 
BMI, kg/m
2
, mean 
(SD)          
      ≤ 18.5 
 
75 (0.5) 7 (0.3) 17 (0.4) 7 (0.2) 
 
     18.6 - 24.9 
5 
445 
(36.3) 964 (36.6) 1 906 (43.5) 
1 
330 
(46.5) <0.001 
      25.0-29.9 
6 
822 
(45.5) 
1 
247 
(47.3) 1 938 (44.3) 
1 
272 
(44.5) 
 
      ≥ 30.0 
 
2 
666 
(17.8) 417 (15.8) 517 (11.8) 250 (8.7) 
 
Hypertension status, N (%)
1
 
        
      Yes 
7 
387 
(49.2) 
1 
224 
(46.5) 1 676 (38.3) 
1 
080 
(37.8) <0.001 
      No 
7 
621 
(50.8) 
1 
411 
(53.6) 2 702 (61.7) 
1 
779 
(62.2) 
 
Smoking, N (%) 
         
      Yes 
4 
562 
(30.4) 630 (23.9) 1 185 (27.1) 462 (16.2) <0.001 
       No 
10 
446 
(69.6) 
2 
005 
(76.1) 3 193 (72.9) 
2 
397 
(83.8) 
 
Alcohol consumption, N 
(%)
2
         
      Abstainer 
2 
075 
(13.8) 198 (7.5) 363 (8.3) 192 (6.7) 
 
      0 - 7 glasses 
11 
320 
(75.4) 
2 
040 
(77.4) 3 399 (77.6) 
2 
143 
(75.0) <0.001 
      8 - 14 glasses 
1 
311 
(8.7) 332 (12.6) 493 (11.3) 409 (14.3) 
 
      >14 glasses 302 (2.0) 65 (2.5) 123 (2.8) 115 (4.0) 
 
Education, N (%) 
         
      < 10 y 
 
6 
699 
(44.6) 839 (31.8) 1 238 (28.3) 597 (20.9) 
 
      10-12 y 
 
6 
098 
(40.6) 
1 
190 
(45.2) 2 087 (47.7) 
1 
271 
(44.5) <0.001 
      > 12 y 2 (14.7) 606 (23.0) 1 053 (24.1) 991 (34.7) 
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Diabetes, N 
(%)           
      Yes 
 
424 (2.8) 54 (2.1) 88 (2.0) 36 (1.3) <0.001 
      No 
 
14 
584 
(97.2) 
2 
581 
(98.0) 4 290 (98.0) 
2 
823 
(98.7) 
 
Total cholesterol, N 
(%)          
      Normal 
 
13 
185 
(87.9) 
2 
339 
(88.8) 3 959 (90.4) 
2 
626 
(91.9) <0.001 
      High 
 
1 
823 
(12.2) 296 (11.2) 419 (9.6) 233 (8.2) 
 
HDL cholesterol, N 
(%)          
      Low 
 
4 
270 
(28.5) 704 (26.7) 1 065 (24.3) 511 (17.9) <0.001 
      Normal 
 
10 
738 
(71.6) 
1 
931 
(73.3) 3 313 (75.7) 
2 
348 
(82.1) 
 
Triglycerides, 
N (%)           
      Normal 
 
8 
671 
(57.8) 
1 
527 
(58.0) 2 863 (65.4) 
1 
993 
(69.7) <0.001 
      High 
 
6 
337 
(42.2) 
1 
108 
(42.0) 1 515 (34.6) 866 (30.3) 
 
Physical activity, N (%) 
        
    Light intensity 
         
            None 
 
1 
443 
(9.7) 128 (5.0) 46 (1.3) 21 (1.0) 
 
            <1 hour 
3 
528 
(23.7) 448 (17.4) 160 (4.4) 69 (3.3) <0.001 
            1-2 hours 
6 
419 
(43.1) 
1 
148 
(44.7) 1 000 (27.4) 651 (31.1) 
 
            ≥3 hours 
3 
488 
(23.4) 847 (32.9) 2 445 (67.0) 
1 
350 
(64.6) 
 
      Vigorous intensity 
         
            None 
 
6 
574 
(65.6) 853 (48.4) - 
 
- 
  
            <1 hour 
3 
454 
(34.4) 911 (51.6) 680 (15.5) 178 (6.2) <0.001 
            1-2 hours - 
 
- 
 
2 665 (60.9) 
1 
604 
(56.1) 
 
            ≥3 hours - 
 
- 
 
1 033 (23.6) 
1 
077 
(37.7) 
 
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in 
square meters), HDL,  
High Density Lipoprotein.
 1 Defined as measured systolic blood pressure ≥ 140, diastolic 
blood pressure ≥ 90 or self-reported use of antihypertensive drugs. 2 Based on consumption 
the last 14 days.  
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Table 3 Hazard ratios of death from CVD and all-causes by PAI (Personal Activity 
Intelligence) score in HUNT 1 (H1) and HUNT 2 (H2) 
 
      PAI Deaths 
Person-
years 
Rate
1
   HR (95% CI)
2
 HR (95% CI)
4
 
 CVD death 
     
 
      Continually low PAI 1 163 264 897 4.4 
1.00 
(Reference)
3 
1.00 
(Reference)
5 
       Decreased PAI 142 47 513 3.0 0.83 (0.69-0.99) 0.87 (0.73-1.04) 
       Increased PAI 172 81 532 2.1 0.81 (0.69-0.96) 0.87 (0.74-1.03) 
       Continually high 
PAI 
83 53 463 1.6 0.56 (0.45-0.70) 0.68 (0.54-0.86) 
         P-trend <0.001 P-trend = 0.001 
 All-cause death 
     
 
      Continually low PAI 3 453 264 897 13.0 1.00 (Reference) 
1.00 
(Reference)
6 
       Decreased PAI 457 47 513 9.6 0.87 (0.79-0.96) 0.92 (0.83-1.01) 
       Increased PAI 549 81 532 6.7 0.81 (0.74-0.89) 0.86 (0.79-0.95) 
       Continually high 
PAI 
323 53 463 6.0 0.69 (0.61-0.77) 0.80 (0.71-0.91) 
 
    
P-trend <0.001 P-trend <0.001 
 CVD: Cardiovascular Disease; HR: Hazard ratio; CI: Confidence intervals. 
Continually low PAI: <100 in HUNT1, <100 in HUNT2, decreased PAI: ≥100 in HUNT1, <100 in HUNT2, 
increased PAI: <100 in HUNT1, ≥100 in HUNT2, continually high PAI: ≥100 in HUNT1, ≥100 in HUNT2.  
1
Calculated per 1000 person-years 
    
 
2
HR adjusted for age (age adjusted time scale) and sex 
3
Stratified by sex 
 
4
HR adjusted for age (age-adjusted time scale), sex, education (<10, 10-12, >12 y), alcohol (abstainer; <8; 8-14; 
>14 glasses per fortnight), smoking status (yes/no), diabetes (yes/no), hypertension (yes/no), BMI (<18.5; 18.5-
24.9; 25-29.9; ≥30 kg/m2), total cholesterol (normal/high), HDL cholesterol (low/normal), triglycerides 
(normal/high) 
5
Stratified by sex, total cholesterol, hypertension and BMI 
6
Stratified by smoking status, BMI, total cholesterol and alcohol 
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Table 4 Deaths from all-cause and CVD by changes in Personal Activity Intelligence (PAI) 
from HUNT 1 to HUNT 2 
  
HUNT 
1 [=0]   
HUNT 
1 [≤50]   
HUNT 
1 [51-
99]   
HUNT 
1 [≥100]   
PAI 
chan
ge 
All-
cause
1
 CVD
2
 
All-
cause
1
 CVD
2
 
All-
cause
1
 CVD
2
 
All-
cause
1
 CVD
2
 
 >75 
1.00 
(Referen
ce) 
1.00 
(Referen
ce) 
1.00 
(Referen
ce) 
1.00 
(Referen
ce) 
1.00 
(Referen
ce) 
1.00 
(Referen
ce) 
1.00 
(Referen
ce) 
1.00 
(referen
ce) 
 45 to 
75 
0.91 
(0.76 - 
1.10) 
0.87 
(0.61 - 
1.25) 
1.05 
(0.84 - 
1.32) 
1.14 
(0.76 - 
1.70) 
1.07 
(0.60 - 
1.91) 
0.91 
(0.31 - 
2.65) 
1.05 
(0.71 - 
1.55) 
0.67 
(0.25 - 
1.85) 
 15 to 
45 
1.01 
(0.88 - 
1.15) 
1.10 
(0.86 - 
1.40) 
1.23 
(1.05 - 
1.44) 
1.27 
(0.96 - 
1.68) 
1.65 
(0.94 - 
2.90) 
0.65 
(0.08 - 
4.98) 
0.89 
(0.49 - 
1.60) 
1.60 
(0.57 - 
4.55) 
-15 to 
15 
1.20 
(1.05 - 
1.37) 
1.34 
(1.05 - 
1.71) 
1.21 
(1.04 - 
1.40) 
1.23 
(0.94 - 
1.60) 
1.39 
(1.03 - 
1.89) 
1.16 
(0.62 - 
2.18) 
1.04 
(0.73 - 
1.49) 
1.39 
(0.66 - 
2.96) 
-15 to 
-45 - - 
1.52 
(1.25 - 
1.86) 
1.49 
(1.05 - 
2.13) 
1.04 
(0.74 - 
1.45) 
0.98 
(0.50 - 
1.90) 
0.97 
(0.71 - 
1.32) 
1.62 
(0.87 - 
3.01) 
-45 to 
-75 - - 
1.45 
(0.84 - 
2.52) 
1.38 
(0.53 - 
3.58) 
1.12 
(0.84 - 
1.49) 
1.11 
(0.63 - 
1.96) 
1.32 
(0.96 - 
1.81) 
1.87 
(0.98 - 
3.55) 
<-75 - - - - 
1.58 
(1.04 - 
2.39) 
2.20 
(1.00 - 
4.82) 
1.06 
(0.83 - 
1.34) 
1.41 
(0.84 - 
2.35) 
P-
trend 0.003 0.006 <0.001 0.048 0.243 0.256 0.518 0.108 
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CVD: cardiovascular disease, PAI change: PAI changes from HUNT1 to HUNT2 categorized in intervals of 30 
PAI 
Hazard ratios adjusted for age (age-adjusted time scale), education (<10y, 10-12 y, >12 y), alcohol (<8; 8-14; 
>14 glasses per fortnight), smoking status (yes/no), diabetes (yes/no), hypertension (yes/no), BMI (<18.5; 18.5-
24.9; 25-29.9; ≥30 kg/m2), total cholesterol (normal/high), HDL cholesterol (low/normal), and triglycerides 
(normal/high). 
1
Stratified by smoking status, BMI, total cholesterol. 
2
Stratified by smoking status, BMI, total cholesterol, sex and hypertension status. 
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